Cardiol Therapeutics Inc. (CRDL.TO)
- Previous Close
2.5000 - Open
2.5000 - Bid 2.4400 x --
- Ask 2.4400 x --
- Day's Range
2.4100 - 2.5000 - 52 Week Range
0.7400 - 2.9400 - Volume
29,743 - Avg. Volume
152,012 - Market Cap (intraday)
167.258M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date May 17, 2024 - May 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.05
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
www.cardiolrx.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CRDL.TO
Performance Overview: CRDL.TO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRDL.TO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRDL.TO
Valuation Measures
Market Cap
167.26M
Enterprise Value
132.50M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.92
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.49
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.71%
Return on Equity (ttm)
-69.93%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-28.13M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
34.93M
Total Debt/Equity (mrq)
0.62%
Levered Free Cash Flow (ttm)
-14.99M
Research Analysis: CRDL.TO
Company Insights: CRDL.TO
CRDL.TO does not have Company Insights